Skip to main navigation
Leap therapeutics
Leap therapeutics
  • About
    • About
    • Contact Us
  • Pipeline
    • Pipeline
    • Sirexatamab (DKN-01) Programs
      • Gastric Cancer
      • Colorectal Cancer
      • Endometrial Cancer
      • Prostate Cancer
      • Lung Cancer
    • FL-501 Program
  • Science
    • Science
    • DKK1
    • Sirexatamab (DKN-01)
    • GDF15
  • Patients
    • Patients
    • Expanded Access
  • Careers
  • Investors
    • Investors
    • Stock Information
    • News Releases
    • Presentations & Events
    • Financial Information
    • Corporate Governance
    • Information Request

News
Releases

image description

News Releases

May 14, 2026
Cypherpunk Technologies Reports First Quarter 2026 Financial Results
Apr 15, 2026
Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard
Mar 16, 2026
Cypherpunk Reports Full Year 2025 Financial Results
Mar 09, 2026
Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)
Jan 22, 2026
Cypherpunk Adds Arjun Khemani as Strategic Advisor
  • image Print Page Print Page
  • image Email Alerts Email Alerts
  • image Contact Us Contact Us
image description
image description
Leap therapeutics
47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA
+1 617 714 0360

Business inquiries
bd@leaptx.com

Investor inquiries
ir@leaptx.com

  • ABOUT
  • CONTACT US
  • CAREERS
  • PIPELINE
  • Sirexatamab (DKN-01) Programs
  • FL-501 Program
  • PATIENTS
  • EXPANDED ACCESS
  • SCIENCE
  • DKK1
  • Sirexatamab (DKN-01)
  • GDF15
  • INVESTORS
  • STOCK INFORMATION
  • NEWS RELEASES
  • PRESENTATIONS & EVENTS
  • FINANCIAL INFORMATION
  • CORPORATE GOVERNANCE
  • INFORMATION REQUEST
  • © 2025 Leap Therapeutics, Inc.
  • All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Cookie Policy